News & Updates
Filter by Specialty:
Real-world data: High rates of complications and unplanned hospital admissions in mHSPC
Seventy percent of patients with metastatic hormone-sensitive prostate cancer (mHSPC) experience disease-related complications, while 59 percent require ≥1 unplanned hospital admission during the course of disease, a study by the Chinese University of Hong Kong (CUHK) has shown.
Real-world data: High rates of complications and unplanned hospital admissions in mHSPC
15 Aug 2023
HILPDA induces development of NASH-driven HCC
Hepatic hypoxia-inducible lipid droplet associated protein (HILPDA) is predictive of survival in patients with nonalcoholic steatohepatitis (NASH)-driven hepatocellular carcinoma (HCC), according to a study.
HILPDA induces development of NASH-driven HCC
12 Aug 2023
Camrelizumab plus chemo combo beneficial in Asian patients with advanced NSCLC
Adding camrelizumab to platinum-based chemotherapy in the neoadjuvant treatment setting appears to improve the rate of pathologic complete response (pCR) in Asian patients with stage IIIA or IIIB non–small cell lung cancer (NSCLC), with manageable toxicity, according to data from the phase II TD-FOREKNOW study.
Camrelizumab plus chemo combo beneficial in Asian patients with advanced NSCLC
10 Aug 2023
Minimally invasive Whipple procedure possible with robotic surgical systems
The Whipple procedure, a complex surgery also known as pancreaticoduodenectomy, is the treatment of choice for patients with pancreatic cancer located at the head of the pancreas.
Minimally invasive Whipple procedure possible with robotic surgical systems
10 Aug 2023
Fosaprepitant dosing frequency makes no difference in CCRT-induced nausea, vomiting prevention
For patients undergoing concurrent chemoradiotherapy (CCRT), treatment with either weekly or every-3-weeks fosaprepitant helps reduce nausea and vomiting caused by CCRT, with no difference in the effect, as reported in a study.
Fosaprepitant dosing frequency makes no difference in CCRT-induced nausea, vomiting prevention
09 Aug 2023
Second-line avelumab works against dMMR/MSI metastatic colorectal cancer
Treatment with the immune checkpoint inhibitor avelumab in the second-line setting confers survival and disease control benefits in patients with deficient mismatch repair and/or microsatellite instability (dMMR/MSI) metastatic colorectal cancer (mCRC) when compared with standard treatment, with a favourable safety profile, according to the results of the phase II SAMCO-PRODIGE 54 trial.
Second-line avelumab works against dMMR/MSI metastatic colorectal cancer
09 Aug 2023
Experts call for early screening to lower colorectal cancer incidence
An expert-led public forum highlighted colorectal health awareness and early screening of people aged 45 and above, as key steps to reduce the burden of colorectal cancer (CRC) in Malaysia.
Experts call for early screening to lower colorectal cancer incidence
09 Aug 2023
Lymph node characteristics predict survival in patients with ovarian cancer
A competing risk model that incorporates lymph node parameters has demonstrated its utility and robustness in evaluating the results of the Cox proportional hazards model analysis among older patients with stage III serious ovarian cancer, reports a study.
